Investigational drug · Phase 2
ALXN2030
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Antibody-Mediated Rejection, Kidney Transplantation, Biopsy-proven Histologic Scores.
Phase 2Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "ALXN2030"
First trial start
2025
Mar 7, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ALXN2030", any sponsor or status.
Conditions studied
As listed on its trial records.
- Antibody-Mediated Rejection
- Kidney Transplantation
- Biopsy-proven Histologic Scores
- AMR
Approved drugs for the same conditions: Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "ALXN2030" as an intervention, largest first.
- Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy ParticipantsActive, not recruiting
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT05501717 · 48 participants · Start Aug 16, 2022 · Primary completion Oct 9, 2025
Drug: ALXN2030; Placebo · For: Healthy
Sites: Harrow, United Kingdom
- Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney TransplantationActive, not recruiting
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT06744647 · 47 participants · Start Mar 7, 2025 · Primary completion Oct 11, 2027
Drug: ALXN2030; Placebo · For: Antibody-Mediated Rejection; Kidney Transplantation; Biopsy-proven Histologic Scores and 1 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Los Angeles, California · 51 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Antibody-Mediated Rejection
- FelzartamabPhase 38 trials
Biogen · Antibody-mediated Rejection, Microvascular Inflammation, Graves' Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.